Eli Lilly has quietly turned a blockbuster obesity and diabetes franchise into one of the market's most intriguing income ...

Eli Lilly is considering all these risks and planning accordingly, and doing so years in advance. That's also why the ...

Eli Lilly (LLY) has shown considerable rally potential, with several occurrences of its stock climbing over 30% in less than ...

Vanda Pharmaceuticals (VNDA) stock rises as the FDA approves its motion sickness therapy Nereus, developed in partnership ...

With UAB and Southern Research, many have assumed that Birmingham is the state’s life sciences giant, but that thinking may ...

But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study.

Novo Nordisk and Eli Lilly are lowering prices of their top-selling obesity drugs Wegovy and Mounjaro in China, according to ...

Lilly’s return to the JP Morgan Healthcare Conference comes as the company seeks to shift the narrative from last year’s ...

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The company still has a robust business that is delivering excellent results and ...

Lilly’s Attain-Maintain Phase III results show that the oral GLP-1 orforglipron can effectively preserve weight loss after injectable therapy, positioning it as a potential long-term maintenance ...

Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) are two prominent names in healthcare that have focused on innovation and growing their respective businesses for decades. But in rece ...

Eli Lilly is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada ...